Pharmacological Inhibition of LIF Signaling Reverses PD-L1-Mediated Immune Suppression in Gastric Cancer

Gastric cancer (GC) is a major clinical challenge, characterized by limited response rates to immune checkpoint inhibitors (ICIs) and persistent immune evasion. Emerging evidence implicates Leukemia Inhibitory Factor (LIF), a cytokine of the IL-6 family, in the modulation of the tumor microenvironment, yet its contribution to PD-L1-mediated immune suppression in GC has not been investigated.